ReviewAnnals of translational medicine2021
A narrative review of prognosis prediction models for non-small cell lung cancer: what kind of predictors should be selected and how to improve models?
Review in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Data-Efficient and Explainable Multimodal Survival Prediction in NSCLC Using Deep Image Embeddings, Clinical Variables, and Gradient-Boosted Trees.Diagnostics (Basel, Switzerland) · 2026Article
- Nutritional Status and Associated Factors Among Adult Gastrointestinal Cancer Patients at a Tertiary Hospital of Ethiopia: A Cross-Sectional Study.Cancer reports (Hoboken, N.J.) · 2026Article
- Heterogeneous treatment effect of immune checkpoint inhibitors by pretreatment prognosis in randomized controlled trials.JNCI cancer spectrum · 2026Article
- Assessing clinician performance using a multi-modality clinical decision-support system for lung cancer prognostication.Scientific reports · 2025Article
- Prognostic score models for acquired resistance to frontline anti-programmed cell death protein 1/programmed death-ligand 1 therapy in metastatic non-small-cell lung cancer.ESMO real world data and digital oncology · 2025Article
- Predictive risk score for isolated brain metastasis in non-small cell lung cancer.Journal of thoracic disease · 2024Article
- Multiomics-Based Feature Extraction and Selection for the Prediction of Lung Cancer Survival.International journal of molecular sciences · 2024Article
- Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing.Journal of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo discover potential predictors and explore how to build better models by summarizing the existing prognostic prediction models of non-small cell lung cancer (NSCLC).
backgroundResearch on clinical prediction models of NSCLC has experienced explosive growth in recent years. As more predictors of prognosis are discovered, the choice of predictors to build models is particularly important, and in the background of more applications of next-generation sequencing technology, gene-related predictors are widely used. As it is more convenient to obtain samples and follow-up data, the prognostic model is preferred by researchers.
methodsPubMed and the Cochrane Library were searched using the items "NSCLC", "prognostic model", "prognosis prediction", and "survival prediction" from 1 January 1980 to 5 May 2021. Reference lists from articles were reviewed and relevant articles were identified.
conclusionsThe performance of gene-related models has not obviously improved. Relative to the innovation and diversity of predictors, it is more important to establish a highly stable model that is convenient for clinical application. Most of the prevalent models are highly biased and referring to PROBAST at the beginning of the study may be able to significantly control the bias. Existing models should be validated in a large external dataset to make a meaningful comparison.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.